Literature DB >> 3379221

Impaired antibody responses in the hyperimmunoglobulin E syndrome.

D Y Leung1, D M Ambrosino, R D Arbeit, J L Newton, R S Geha.   

Abstract

Patients with the hyper-IgE (HIE) syndrome have recurrent bacterial infections with Staphylococcus aureus and other polysaccharide encapsulated organisms. To determine whether an impairment of the antibody response to polysaccharide antigens contributes to infections in this syndrome, we measured serum antibody to the teichoic acid of S. aureus and to the capsular polysaccharide of Haemophilus influenzae type b. Compared to control subjects who had no history of S. aureus infections (N = 14), sera from patients with HIE (N = 9) lacked the expected elevation of serum antibody to teichoic acid (p greater than 0.05) and had significantly lower levels of this antibody than sera from 14 patients with atopic dermatitis, complicated by recurrent cutaneous S. aureus infections (p less than 0.01). After immunization with the capsular polysaccharide of Haemophilus influenzae type of vaccine, the antibody response of patients with HIE was significantly impaired compared to that of age-matched control subjects (p = 0.01). Although patients with HIE syndrome had normal total IgG levels, most patients with HIE but not patients with atopic dermatitis had IgG2 subclass deficiency. Defective antibody responses in patients with HIE were not restricted to polysaccharide antigens because the serum levels of antitetanus toxoid antibody in these patients were significantly lower than that of control subjects (p less than 0.001). Impaired antigen-specific antibody responses in patients with HIE syndrome may contribute to their increased susceptibility to infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379221     DOI: 10.1016/0091-6749(88)90873-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

1.  Evaluation of the Role of stat3 in Antibody and TH17-Mediated Responses to Pneumococcal Immunization and Infection by Use of a Mouse Model of Autosomal Dominant Hyper-IgE Syndrome.

Authors:  Kristin Moffitt; Elaine Cheung; John Manis; Richard Malley
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

2.  IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts.

Authors:  Lucinda J Berglund; Danielle T Avery; Cindy S Ma; Leen Moens; Elissa K Deenick; Jacinta Bustamante; Stephanie Boisson-Dupuis; Melanie Wong; Stephen Adelstein; Peter D Arkwright; Rosa Bacchetta; Liliana Bezrodnik; Harjit Dadi; Chaim M Roifman; David A Fulcher; John B Ziegler; Joanne M Smart; Masao Kobayashi; Capucine Picard; Anne Durandy; Matthew C Cook; Jean-Laurent Casanova; Gulbu Uzel; Stuart G Tangye
Journal:  Blood       Date:  2013-10-24       Impact factor: 22.113

3.  Hyper-response of serum IgG1 to Staphylococcus aureus peptidoglycan in patients with hyper-IgE syndrome.

Authors:  A Ishizaka; K Kojima; Y Sakiyama; S Matsumoto; K Kuwajima; Y Wagatsuma; R Shibata; K Joh
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

Review 4.  Cytokine-Mediated Regulation of Plasma Cell Generation: IL-21 Takes Center Stage.

Authors:  Leen Moens; Stuart G Tangye
Journal:  Front Immunol       Date:  2014-02-18       Impact factor: 7.561

5.  T-cell STAT3 is required for the maintenance of humoral immunity to LCMV.

Authors:  David R McIlwain; Melanie Grusdat; Vitaly I Pozdeev; Haifeng C Xu; Prashant Shinde; Colin Reardon; Zhenyue Hao; Marc Beyer; Andreas Bergthaler; Dieter Häussinger; Garry P Nolan; Karl S Lang; Philipp A Lang
Journal:  Eur J Immunol       Date:  2014-12-15       Impact factor: 5.532

6.  PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients.

Authors:  Yuan Zhang; Chi A Ma; Monica G Lawrence; Timothy J Break; Michael P O'Connell; Jonathan J Lyons; Diego B López; John S Barber; Yongge Zhao; Daniel L Barber; Alexandra F Freeman; Steven M Holland; Michail S Lionakis; Joshua D Milner
Journal:  J Exp Med       Date:  2017-07-14       Impact factor: 14.307

7.  B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans.

Authors:  Danielle T Avery; Elissa K Deenick; Cindy S Ma; Santi Suryani; Nicholas Simpson; Gary Y Chew; Tyani D Chan; Umamainthan Palendira; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Sharon Choo; Karl E Bleasel; Jane Peake; Cecile King; Martyn A French; Dan Engelhard; Sami Al-Hajjar; Saleh Al-Muhsen; Klaus Magdorf; Joachim Roesler; Peter D Arkwright; Pravin Hissaria; D Sean Riminton; Melanie Wong; Robert Brink; David A Fulcher; Jean-Laurent Casanova; Matthew C Cook; Stuart G Tangye
Journal:  J Exp Med       Date:  2010-01-04       Impact factor: 14.307

8.  STAT3 signaling induces the differentiation of human ICOS(+) CD4 T cells helping B lymphocytes.

Authors:  Laure Ysebrant de Lendonck; Fouad Eddahri; Yves Delmarcelle; Muriel Nguyen; Oberdan Leo; Stanislas Goriely; Arnaud Marchant
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

9.  Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells.

Authors:  Elissa K Deenick; Danielle T Avery; Anna Chan; Lucinda J Berglund; Megan L Ives; Leen Moens; Jennifer L Stoddard; Jacinta Bustamante; Stephanie Boisson-Dupuis; Miyuki Tsumura; Masao Kobayashi; Peter D Arkwright; Diana Averbuch; Dan Engelhard; Joachim Roesler; Jane Peake; Melanie Wong; Stephen Adelstein; Sharon Choo; Joanne M Smart; Martyn A French; David A Fulcher; Matthew C Cook; Capucine Picard; Anne Durandy; Christoph Klein; Steven M Holland; Gulbu Uzel; Jean-Laurent Casanova; Cindy S Ma; Stuart G Tangye
Journal:  J Exp Med       Date:  2013-11-11       Impact factor: 14.307

Review 10.  Signal Transducer and Activator of Transcription 3 Control of Human T and B Cell Responses.

Authors:  Elissa K Deenick; Simon J Pelham; Alisa Kane; Cindy S Ma
Journal:  Front Immunol       Date:  2018-02-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.